Recent findings may change the management of patients with asymptomatic, advanced-stage follicular lymphoma (FL): initial treatment with rituximab was found to delay significantly the need for new therapy, reported Kirit M. Ardeshna, MD, of the University College London Hospitals, London, UK. The study was presented at the 52nd American Society of Hematology Annual Meeting and Exposition.
Sign in with your MPR account
Keep me signed in Forgot your password?
REGISTER FOR FREE WITH A MPR ACCOUNT
Enter your MPR registration email address to receive a new password.